Life sciences

7 stories
Biotech-focused Atlas Venture moves into new digs in Tech Square
Atlas Venture partners Peter Barrett and Bruce Booth. (Photo by Scott Kirsner / BetaBoston.)
If you haven't been following the breakup of the 35-year-old venture capital firm Atlas Venture, which once invested in both tech and biotech, partner Peter Barrett sums it up this way: "In this divorce, the life sciences side kept the name, and the tech side got the house." So Atlas's team of tech investors is casting about for a new name, but staying in East Cambridge. And the biotech crew, still known as Atlas, just moved into new offices yesterday atop 400 Technology Square in Cambridge, midway between the Kendall and Central stations on the Red Line. Read More
Spawning more startups
PureTech pockets $50 million to bring life sciences ideas out of the lab
PureTech founder and CEO Daphne Zohar, center. (Photo by Scott Zuehlke, courtesy PureTech.)
The big players of the biopharma world descend on San Francisco next week for the annual JP Morgan Healthcare Conference, and in advance of it, Boston-based PureTech is announcing it has raised $50 million in new funding. PureTech takes successful research out of academic labs, and assembles teams that can move it toward commercialization. Among its projects are startup companies focused on obesity, hair growth, drug delivery without needles, and therapeutic video games. Read More
In the lab
Boston angel investor Andy Palmer's trip from rugby to biotech
Andy Palmer

The rise of super angels in Silicon Valley, Ron Conway, Paul Graham, Dave McClure, and the like is one thing that people point to as a vast advantage of the West Coast tech scene over the East Coast innovation community. The secret is, we have super angels on this side of the continent, many playing key roles in the growth of Boston's technology ecosystem.

Read More
make it rain
RainDance adds $16.5M for new biopsy technology
Image taken from RainDance website.

RainDance Technologies Inc., a Billerica company using genomics tools to design tests for the early detection of cancer and other diseases, said that it has closed a $16.5 million Series E financing round extension.

New investors include GE Ventures and Northgate Capital. All existing financial investors participated in the round as well, RainDance said in a press release.

Read More